NextGen geneCore 161 Somatic comprehensive panel ( TMB+MSI+PDL1 22C3)
NextGen geneCore 161 Somatic comprehensive panel ( TMB+MMR+PDL1 SP263)** Price
Brief Details
What Is a NextGen geneCore 161 Somatic Comprehensive Panel?
The NextGen geneCore 161 Somatic Comprehensive Panel is an advanced and comprehensive cancer gene panel that uses Next-Generation Sequencing (NGS) technology to analyse cancer cells in your tumour tissue. This test examines 161 specific genes known to play important roles in cancer development and progression.
The panel helps identify genetic changes (mutations) in your cancer that can guide your doctor in choosing the most effective, personalised treatment options for your specific type of cancer.
What Does the NextGen geneCore 161 Somatic Comprehensive Panel Measure?
The NextGen geneCore 161 Somatic Comprehensive Panel provides detailed genetic information to support precision cancer care:
- Actionable mutations: Identifies genetic changes that can be targeted with specific cancer medicines.
- Treatment guidance: Helps doctors select the most suitable targeted therapies or immunotherapy options.
- Tumour mutational burden (TMB): Measures the total number of mutations in your cancer cells.
- Microsatellite instability (MSI): Detects DNA repair defects that may respond well to certain treatments.
- PD-L1 expression: Evaluates whether your tumour may respond to immunotherapy treatments.
- Drug resistance markers: Identifies mutations that might make certain treatments less effective.
- Clinical trial eligibility: Helps determine if you qualify for investigational cancer treatments.
NextGen geneCore 161 Somatic Comprehensive Panel: Who Needs It and Why It's Done
What Symptoms May Call for a NextGen geneCore 161 Somatic Comprehensive Panel?
The NextGen geneCore 161 Somatic Comprehensive Panel is ordered after a cancer diagnosis has been confirmed, not based on symptoms. However, the symptoms that initially lead to cancer detection may include:
- Unexplained weight loss that continues despite normal eating
- Persistent fatigue that doesn't improve with rest
- Unusual lumps or swellings anywhere in your body
- Changes in bowel or bladder habits that last for weeks
- Persistent cough or hoarseness without an obvious cause
- Sores or wounds that don't heal properly
- Unusual bleeding or discharge from any body opening
Who Should Get a NextGen geneCore 161 Somatic Comprehensive Panel?
Your oncologist may recommend this comprehensive cancer gene panel if you fall into specific patient groups:
- Patients with advanced solid tumours: Including lung cancer, colorectal cancer, gastric cancer, pancreatic cancer, or uterine cancers
- Those with metastatic cancer: When cancer has spread to other parts of your body
- Patients with rare or aggressive cancers: To identify potential treatment options beyond standard care
- Individuals whose cancer has returned: As the genetic makeup may have changed since initial treatment
- Patients not responding to standard treatments: To find alternative therapeutic approaches
- Those with genitourinary cancers or kidney cancer: Where targeted therapy options may be available
Why Is a NextGen geneCore 161 Somatic Comprehensive Panel Done?
This test moves beyond traditional cancer treatment approaches to provide personalised medicine based on your tumour's unique genetic profile, helping doctors select the most effective treatments while avoiding those unlikely to work.
Importance of a NextGen geneCore 161 Somatic Comprehensive Panel
The NextGen geneCore 161 Somatic Comprehensive Panel represents a cornerstone of modern precision oncology. By identifying actionable biomarkers, the panel directly informs the selection of targeted therapies designed to attack cancer cells with specific mutations while causing less harm to healthy cells. This approach leads to more effective treatment strategies and potentially better outcomes, and reduces exposure to treatments that wouldn't have worked for your specific cancer type.
NextGen geneCore 161 Somatic Comprehensive Panel Booking & Reports – Metropolis Healthcare India
How to Book a NextGen geneCore 161 Somatic Comprehensive Panel?
- Simple Online Booking
Booking can be done through the Metropolis Healthcare App or website. Select the 'NextGen geneCore 161 Somatic Comprehensive Panel', choose a convenient time slot, and visit the pathology lab.
- Sample Tracking Updates
Stay informed at every step. From collection to testing, you can track your sample directly through the Metropolis Healthcare website.
- Accurate Laboratory Testing
Your sample is processed at our NABL & CAP accredited laboratories, where expert technicians ensure accurate results.
- Quick & Easy Reports
Receive your test reports promptly via email, WhatsApp, or by downloading them directly from the Metropolis Healthcare website or app.
Is Home Sample Collection for the NextGen geneCore 161 Somatic Comprehensive Panel Available Near You?
Home sample collection is not required for this test, as it analyses genetic material from tumour tissue that has already been collected during your biopsy. Simply coordinate with your oncology team to ensure your tissue sample is available and properly prepared. With over 10,000+ touchpoints across India, Metropolis Healthcare makes advanced cancer genetic testing accessible and convenient, backed by strict safety protocols and trusted accuracy for every step of your cancer care journey.
How Long Does It Take to Get a NextGen geneCore 161 Somatic Comprehensive Panel Report?
Reports are usually available within 20 days once the sample reaches the lab.
Note: Reporting time may vary depending on your location.
Where Can I See or Get NextGen geneCore 161 Somatic Comprehensive Panel Results?
Test results from Metropolis Healthcare can be accessed through multiple convenient channels. You can log in to the Metropolis website using your credentials or use the Metropolis Healthcare App to view and download your reports. Additionally, test reports are sent via email or WhatsApp, and you also have the option to collect a physical copy directly from the lab.
Interpreting NextGen geneCore 161 Somatic Comprehensive Panel Results
What Your NextGen geneCore 161 Somatic Comprehensive Panel Results May Indicate
Your NextGen geneCore 161 Somatic Comprehensive Panel results will provide a detailed genetic profile rather than simple normal or abnormal values. Here's what the different components mean:
|
Parameter |
What It Measures |
Clinical Significance |
|
Gene Mutations |
Specific genetic changes in 161 cancer-related genes |
Identifies actionable targets for personalised treatment. |
|
TMB (Tumour Mutational Burden) |
Number of mutations per megabase (mut/Mb) |
Higher TMB may predict a better response to immunotherapy. |
|
MSI (Microsatellite Instability) |
The DNA repair system functions |
MSI-high tumours often respond well to certain treatments. |
|
PD-L1 Expression |
Percentage of positive tumour/immune cells |
Helps predict response to immunotherapy treatments. |
Conditions that May Affect NextGen geneCore 161 Somatic Comprehensive Panel Accuracy
Several factors can influence the quality and accuracy of your NextGen geneCore 161 Somatic Comprehensive Panel results:
- Sample quality: The age and preservation of your tumour tissue sample affect DNA quality.
- Tumour cell percentage: Samples with too few cancer cells may not provide reliable results.
- Previous treatments: Chemotherapy or radiation may alter the genetic profile of remaining cancer cells.
- Sample contamination: Normal tissue mixed with tumour tissue can dilute the cancer DNA.
- Storage conditions: Improper storage of tissue samples can degrade DNA quality.
- Technical limitations: Some genetic changes may be below the detection threshold of the test.
How Is a NextGen geneCore 161 Somatic Comprehensive Panel Done?
The NextGen geneCore 161 Somatic Comprehensive Panel process involves several carefully coordinated steps:
- Tissue sample preparation: Your previously collected tumour tissue (FFPE block) is processed in the laboratory.
- DNA extraction: Genetic material is carefully extracted from the cancer cells in your tissue sample.
- Quality assessment: Laboratory technicians verify that the DNA is suitable for testing.
- Next-generation sequencing: Advanced machines read the genetic code of 161 cancer-related genes.
- Data analysis: Sophisticated computer programs identify mutations and genetic changes.
- TMB and MSI analysis: Additional testing measures mutation burden and DNA repair function.
- PD-L1 testing: Immunohistochemistry determines protein expression levels.
- Report generation: Results are compiled into a comprehensive report for your oncologist.
How Should You Prepare for a NextGen geneCore 161 Somatic Comprehensive Panel?
No physical preparation is required for this test, as it uses previously collected tumour tissue:
- Coordinate with your oncology team: Ensure your tissue sample is available and properly prepared.
- Provide clinical history: Share your complete cancer diagnosis and treatment history with your doctor.
- Gather pathology reports: Bring your histopathology and immunohistochemistry (IHC) reports.
- List all medications: Inform your healthcare team about current and recent cancer treatments.
Diseases that a NextGen geneCore 161 Somatic Comprehensive Panel Can Help Detect
This comprehensive panel helps guide treatment for various solid tumour types:
- Lung cancer
- Colorectal cancer
- Gastric cancer
- Pancreatic cancer
- Uterine cancers
- Genitourinary cancers
- Kidney cancer
- Melanoma
NextGen geneCore 161 Somatic Comprehensive Panel/Packages that You Can Book With Metropolis Healthcare
Metropolis Healthcare offers several related tests and packages that complement cancer genetic testing:
|
Test/Package Name |
Purpose/Highlights |
|
Specific MSI testing for Lynch syndrome and treatment response prediction |
|
|
Comprehensive genetic testing for inherited cancer risk assessment |
|
|
Comprehensive cancer screening package designed for women |
|
|
Complete cancer screening package tailored for men |
Frequently asked questions
Find quick answers to the most common questions about health tests, bookings, and reports.
Regular exercise, a balanced diet, avoiding smoking, maintaining a healthy weight, and managing stress all help reduce heart disease risk.
Common signs include irritability, trouble sleeping, headaches, difficulty concentrating, and muscle tension.
Ratings & Reviews
We're satisfying our customers every day since 1980.
Choose precision On time, every time!
- 98% on time collections with a 60 minutes promise
- Real-time tracking of phlebotomist arrival and report generation
- Fully digital report delivery—view from mobile or desktop instantly
- Continuous monitoring of turnaround times to ensure accuracy and speed
- Dedicated support team to resolve any delays or queries quickly
Why Metropolis Healthcare?
Metropolis has been present for over 40 years in the market.
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
0
Years of experience
170+
Advanced Labs
Trusted by
Leading Doctors & Hospitals
2,000+
Scientific Officers
Proficiency Testing
for Accurate Reports
Latest Blogs & News
Stay informed with our expert insights and updates.
About Us
Metropolis Healthcare is a leading diagnostic service provider in India. We are a team of dedicated professionals committed to ensuring you and your family receive the most accurate and timely healthcare solutions. We believe in making health care accessible, affordable and evidence-based. Our expert panel are equipped with the latest technology and manned by a certified team of over 4000+ technicians.
In diagnostic services, we have more than three decades of experience servicing diverse stakeholders health advantage packages for men, women and seniors, genetic fitness & corporation in over 650+ tests like Oncology, Neurology, Gynaecology, Haematology, and many more. Our diagnostic services are located in leading doctors and clinics and serve over 15+ cities in India.